Search Bar & Filters
Found 61 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of the drug cemiplimab as adjuvant immunotherapy for patients with stage II-IIIA non-small cell lung cancer NSCLC who have had their tumors surgically removed and who have not received prior chemotherapy. This phase III trial focuses on comparing cemiplimab treatment to observation alone, specifically in patients whose tumors show PD-L1 expression of 1% or higher. The main goal is to measure disease-free survival, which means the time patients remain free from cancer recurrence or death. Participants in the experimental group receive cemiplimab intravenously at 350 mg every 3 weeks for 4 cycles, followed by 700 mg every 6 weeks for up to 6 cycles or until cancer returns or unacceptable side effects occur. Another group is assigned to observation without additional treatment. The study treatment schedules include specific dosing intervals and duration, designed to monitor the impact of cemiplimab on preventing cancer recurrence after surgery. Throughout the trial, participants will be monitored regularly for disease recurrence and side effects. Assessments include tracking disease-free survival and overall survival for up to approximately 59 months from randomization. Safety will be evaluated by documenting adverse events from the time of informed consent until the trial ends. Participants must comply with scheduled visits and testing to help researchers collect information on treatment effects and safety over the long term.
Actively Recruiting
Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and anti-tumor effects of two drugs, Patritumab Deruxtecan HER3-DXd and Trastuzumab Deruxtecan T-DXd, when used together in people with hormone receptor-positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer. This trial includes both dose regimen determination and dose expansion phases to find the optimal treatment combination and dose. Participants will receive one of several treatment regimens combination regimen A or B of HER3-DXd and T-DXd, a regimen based on earlier study data, or T-DXd alone. Treatments are given intravenously and continue until disease progression, unacceptable side effects, death, or trial closure. The study is randomized and open-label, meaning participants are assigned to different groups without masking. During the study, participants will be closely monitored for side effects and tumor response using imaging and laboratory tests over approximately 4.5 to 6 years. Researchers will assess treatment safety by recording adverse events and evaluate anti-tumor activity with standardized criteria. Blood samples will be collected at various times to measure drug levels. The study aims to find the best dosing while ensuring participant safety and treatment effectiveness over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of acalabrutinib combined with the standard chemotherapy regimen R-CHOP for patients with mantle cell lymphoma MCL who have not received prior treatment. This phase II, single-arm, open-label study in Spain aims to understand how well this combination works as a first-line treatment and to monitor patient safety during the process. The study involves approximately 55 participants across multiple centers. Participants will receive acalabrutinib orally twice daily along with up to six 21-day cycles of R-CHOP chemotherapy during the induction phase. After completing six cycles, those who tolerate the treatment and whose disease is not progressing will continue acalabrutinib alone. Participants who respond to treatment will also receive maintenance doses of rituximab every other 28-day cycle for up to 12 doses. Following this maintenance, acalabrutinib monotherapy continues until disease progression or treatment discontinuation. Throughout the study, participants will be regularly assessed with clinical evaluations, including monitoring for response to treatment and safety. The main outcome measured is the best overall response rate approximately one year after starting acalabrutinib. Secondary outcomes include time to response, duration of response, progression-free survival, overall survival, and safety profiles. Participants will be followed from screening until withdrawal, loss to follow-up, death, or study end, with a maximum follow-up of about 30 months after the last participant enrolls.
Actively Recruiting
Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness of riliprubart compared to the usual treatment of intravenous immunoglobulin IVIg in adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP who are currently receiving maintenance IVIg therapy. This Phase 3 randomized study aims to understand how well riliprubart works in this group over a study duration of up to 109 weeks, including screening, treatment, and follow-up periods. Participants are randomly assigned to one of two groups one group receives riliprubart along with a placebo IVIg infusion for 24 weeks, followed by an open-label extension phase with riliprubart for another 24 weeks the other group continues IVIg treatment with a placebo riliprubart for 24 weeks, then also enters the open-label riliprubart extension. Treatments are given as intravenous or subcutaneous infusions, and dosing follows established maintenance regimens. During the study, participants will have regular assessments to monitor their response to treatment. These include measuring disability and fatigue scales, grip strength, and relapse rates from baseline through various time points up to week 109. Safety is monitored by tracking treatment-emergent adverse events and antibody development. Participants are followed closely through scheduled visits to evaluate changes in their condition and overall health status throughout the study.
Actively Recruiting
Healthy Volunteer
The WILLEM study is a multicenter observational trial focusing on high-risk cardiac patients with arrhythmias or abnormal ECG patterns. It aims to validate a cloud-based AI-powered ECG analysis platform called Willem173, which is designed to detect and predict cardiac abnormalities. The study compares the AI diagnoses with cardiologists evaluations and assesses the platforms ability to delay or avoid severe cardiac events such as sudden death. Participants include patients with relevant cardiac arrhythmias or diseases and at least one ECG record with over one year of follow-up data. Participants are divided into two groups a training group to develop new AI methodologies and a test group to evaluate the AIs performance and avoid overfitting. The AI platform analyzes cardiac electrical signals lasting 10 seconds or more, collected from various devices including hospital ECG machines, Holter monitors, wearable ECG patches, and telemedicine interfaces. Cardiology experts review all data to label arrhythmias and patterns. Both retrospective and prospective patient data are used. During the study, participants provide ECG data and clinical information for analysis. Researchers monitor primary outcomes such as real-time detection of cardiac arrhythmias within minutes of ECG recording. Secondary outcomes include survival, major cardiovascular events, rehospitalization, and quality of life measured one year after the initial ECG or enrollment. Informed consent is obtained from patients or authorized relatives if patients cannot consent themselves. The study is conducted until November 2026, with ongoing data collection and evaluation.
1-10 of 61
1